Dapagliflozin
7 NDCs across 2 manufacturers|2 Generic,5 Brand
Dapagliflozin is used to treat type 2 diabetes mellitus and heart failure, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jan 8, 2014, and the first generic was approved Apr 6, 2026. FDA's Orange Book lists 32 AB-rated (therapeutically equivalent) products for this ingredient.
Dapagliflozin is available as 7 NDCs from 2 manufacturers (2 generic, 5 brand), with NADAC prices from $0.16 to $12.08 per EA — the most expensive product costs about 74× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
7
2G / 5B
Manufacturers
2
competing in market
Price Spread
$0.16 – $12.08
per EA
7d Activity
avg +0.0% WoW · of 7 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
AstraZeneca Pharmaceuticals LP manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Sodium-Glucose Cotransporter 2 Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing DAPAGLIFLOZIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
FARXIGA 10 MG TABLET | $12.0770 per EA | 0.00% |
FARXIGA 10 MG TABLET | $12.0770 per EA | 0.00% |
FARXIGA 10 MG TABLET | $12.0770 per EA | 0.00% |
FARXIGA 5 MG TABLET | $12.0758 per EA | 0.00% |
FARXIGA 5 MG TABLET | $12.0758 per EA | 0.00% |
DAPAGLIFLOZIN 10 MG TABLET | $0.1839 per EA | — |
DAPAGLIFLOZIN 5 MG TABLET | $0.1627 per EA | — |
Frequently Asked Questions
What is Dapagliflozin used to treat?
Dapagliflozin is used to treat type 2 diabetes mellitus and heart failure, per the National Library of Medicine's MED-RT classification.
When did Dapagliflozin become available as a generic?
FDA approved the first generic Dapagliflozin (ANDA) on Apr 6, 2026. The Orange Book currently lists 32 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How many Dapagliflozin products are on the market?
The Dapagliflozin drug market contains 7 NDCs from 2 manufacturers — 2 generic and 5 brand products.
What is the price range for Dapagliflozin?
NADAC reference prices for Dapagliflozin range from $0.1627 to $12.0770 per EA — the most expensive product costs about 74× the cheapest.
Is generic Dapagliflozin cheaper than brand?
The average generic NADAC for Dapagliflozin is $0.1733 per EA, versus $12.0765 for brand-labeled products — brand versions average about 70× the generic price.
Which manufacturers make Dapagliflozin?
2 manufacturers list Dapagliflozin in NADAC. Ranked by number of NDCs, the largest are AstraZeneca Pharmaceuticals LP (5), Prasco Laboratories (2).
How has the price of Dapagliflozin changed recently?
Over the past 7 days, 0 Dapagliflozin NDCs rose and 0 fell, with a market-wide average change of +0.0%.